An open, repeat dose study to investigate the effect of co-administration of the combined oral contraceptive pill (COC) and GW273225 on the pharmacokinetics of the COC and to investigate the effects of the COC on the pharmacokinetics of GW273225 in healthy female subjects
Latest Information Update: 15 Jul 2023
At a glance
- Drugs GW 273225 (Primary) ; Ethinylestradiol/levonorgestrel
- Indications Bipolar disorders; Epilepsy
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 01 Aug 2007 New trial record.